Aradigm Corporation (NASDAQ:ARDM) was founded in 1991 and is headquartered in Hayward, California, with 23 full-time employees. It is a specialty pharmaceutical company focusing on the development and commercialization of products for the treatment and prevention of severe respiratory diseases.
Aradigm Corporation (ARDM):
Aradigm Corporation’s main drug candidate is a patented formulation of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin, which is delivered by inhalation for the treatment of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, Cystic fibrosis and non-tuberculous mycobacteria.
Aradigm Corporation is also developing inhaled ciprofloxacin preparations for the treatment of cystic fibrosis patients, and has tested the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhaled anthrax, tularemia, Melioidosis and pneumonic plague.
Aradigm Corporation and Grifols, SA have signed a cooperation agreement.
Aradigm Corporation (ARDM) history and team:
Since 1991, Aradigm has attracted a team of outstanding scientists, engineers and clinical experts who have been at the forefront of the development of advanced inhalation delivery products.
For example, the team was the first to launch the AERx® lung delivery platform, which has tested drugs and biologics on thousands of patients, including insulin, fentanyl, erythropoietin and nicotine.
With rich experience and expertise in inhalation delivery, Aradigm has unique advantages and can develop its own product portfolio to treat patients with severe respiratory diseases.
The current product pipeline includes an inhaled antibiotic for the treatment of bronchiectasis, cystic fibrosis and biological defense, and inhaled nicotine for smoking cessation.